MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

BACKGROUND: Targeting of MDSCs is a major clinical challenge in the era of immunotherapy. Antibodies which deplete MDSCs in murine models can reactivate T cell responses. In humans such approaches have not developed due to difficulties in identifying targets amenable to clinical translation. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Fultang, Livingstone, Panetti, Silvia, Ng, Margaret, Collins, Paul, Graef, Suzanne, Rizkalla, Nagy, Booth, Sarah, Lenton, Richard, Noyvert, Boris, Shannon-Lowe, Claire, Middleton, Gary, Mussai, Francis, De Santo, Carmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796554/
https://www.ncbi.nlm.nih.gov/pubmed/31462392
http://dx.doi.org/10.1016/j.ebiom.2019.08.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796554/
https://www.ncbi.nlm.nih.gov/pubmed/31462392
http://dx.doi.org/10.1016/j.ebiom.2019.08.025

Ejemplares similares